avanti polar lipids/MPLA (PHAD®)/5mg/699800P-5mg-免疫在线蚂蚁淘旗下平台

当前位置：首页 > 产品中心 > Sphingomyelin > avanti polar lipids/MPLA (PHAD®)/5mg/699800P-5mg

商品详细avanti polar lipids/MPLA (PHAD®)/5mg/699800P-5mg

avanti polar lipids/MPLA (PHAD®)/5mg/699800P-5mg

商品编号： 699800P-5mg

品牌： Avanti

市场价： ¥18945.00

美元价： 14205.00

产地：美国(厂家直采)

公司：

产品分类：酯

公司分类： Sphingomyelin

联系Q Q： 3392242852

电话号码： 4000-520-616

电子邮箱： info@ebiomall.com

立即询价

商品介绍

699800 | MPLA (PHAD®)

Monophosphoryl Lipid A (Synthetic) (PHAD®)

Info

MPLA (PHAD®)

Monophosphoryl Lipid A (Synthetic) (PHAD®)

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

PHAD® is a synthetic structural analog of monophosphoryl Lipid A (MPLA) that has been shown to boost the immune system through activation of the toll-like receptor 4 (TLR4) resulting in production of proinflammatory cytokines and antigen-specific effector CD4+ and memory CD8+ T cells. Also referred to as GLA, this adjuvant has been administered to well over 1000 human subjects without serious adverse events. PHAD® is available in bulk quantities for vaccine development and commercial manufacturing.

Stimulatory effect of PHAD®, 3D-PHAD®, and 3D(6-acyl)-PHAD® on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD®, 3D-PHAD®, or 3D(6-acyl)-PHAD® for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.

Adjuvant Activity

PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).

Data

Hygroscopic

Light Sensitive

Molecular Formula

C₉₆H₁₈₄N₃O₂₂P

Percent Composition

C 65.38%, H 10.52%, N 2.38% ,O 19.96%, P 1.76

Purity

> 99%

Stability

1 Years

Storage Temperature

-20°C

CAS Number

1246298-63-4 CAS Registry Number is a Registered Trademark of the American Chemical Society

FormulaWeight

1763.469

Exact Mass

1762.311

Synonyms

PHAD® phosphorylated hexaacyl disaccharideGlycopyranoside Lipid A (GLA)

Downloads

ChemDraw File
3D Structure
Structure
Brochure
699800 Adjuvant Data
Safety Data Sheet

References

Fisher BS, Dambrauskas N, Trakhimets O, Andrade DV, Smedley J, Sodora DL, Sather DN. Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates. PLoS One. 2020 May 29;15(5):e0233577. doi: 10.1371/journal.pone.0233577. PMID: 32470041; PMCID: PMC7259690.

PubMed ID: 32470041

Richard K, Perkins DJ, Harberts EM, Song Y, Gopalakrishnan A, Shirey KA, Lai W, Vlk A, Mahurkar A, Nallar S, Hawkins LD, Ernst RK, Vogel SN. Dissociation of TRIF bias and adjuvanticity. Vaccine. 2020 Jun 2;38(27):4298-4308. doi: 10.1016/j.vaccine.2020.04.042. Epub 2020 May 7. PMID: 32389496; PMCID: PMC7302928.

PubMed ID: 32389496

Boudousquié C, Boand V, Lingre E, Dutoit L, Balint K, Danilo M, Harari A, Gannon PO, Kandalaft LE. Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. Vaccines (Basel). 2020 Jan 14;8(1):E25. doi: 10.3390/vaccines8010025. PMID: 31947581.

PubMed ID: 31947581

Verma A, Schmidt BA, Elizaldi SR, Nguyen NK, Walter KA, Beck Z, Trinh HV, Dinsarapu AR, Lakshmanappa YS, Rane NN, Matyas GR, Rao M, Shen X, Tomaras GD, LaBranche CC, Reimann KA, Foehl DH, Gach JS, Forthal DN, Kozlowski PA, Amara RR, Iyer SS. Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. J Virol. 2019 Dec 11;JVI.01737-19. doi: 10.1128/JVI.01737-19. [Epub ahead of print]. PMID: 31827000.

PubMed ID: 31827000

Wang L, Wang Z, Qin Y, Liang W. Delivered antigen peptides to resident CD8α+ DCs in lymph node by micelle-based vaccine augment antigen-specific CD8+ effector T cell response. Eur J Pharm Biopharm. 2020 Feb;147:76-86. doi: 10.1016/j.ejpb.2019.12.013. Epub 2019 Dec 28. PMID: 31887349.

PubMed ID: 31887349

Hernandez A, Luan L, Stothers CL, Patil NK, Fults JB, Fensterheim BA, Guo Y, Wang J, Sherwood ER, Bohannon JK. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. Crit Care Med. 2019 Nov;47(11):e930-e938. doi: 10.1097/CCM.0000000000003967.

PubMed ID: 31567352

Maynard S, Marshall JD, MacGill RS, Yu L, Cann JA, Cheng LI, McCarthy MP, Cayatte C, Robbins SH. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. BMC Cancer. 2019 Jun 6;19(1):540. doi: 10.1186/s12885-019-5725-y.

PubMed ID: 31170937

Belnoue E, Mayol JF, Carboni S, Di Berardino Besson W, Dupuychaffray E, Nelde A, Stevanovic S, Santiago-Raber ML, Walker PR, Derouazi M. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight. 2019 Apr 23;5. pii: 127305. doi: 10.1172/jci.insight.127305.

PubMed ID: 31013258

Zhao Z, Hu Y, Harmon T, Pentel P, Ehrich M, Zhang C. Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine. Mol Pharm. 2019 Jun 3;16(6):2766-2775. doi: 10.1021/acs.molpharmaceut.9b00279. Epub 2019 May 22.

PubMed ID: 31075204

Liang T, Leung LM, Opene B, Fondrie WE, Lee YI, Chandler CE, Yoon SH, Doi Y, Ernst RK, Goodlett DR. Rapid microbial identification and antibiotic resistance detection by mass spectrometric analysis of membrane lipids. Anal Chem. 2018 Dec 20. doi: 10.1021/acs.analchem.8b02611. [Epub ahead of print]

PubMed ID: 30571097

Valencia S, Gill RB, Dowdell KC, Wang Y, Hornung R, Bowman JJ, Lacayo JC, Cohen JI. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model. Vaccine. 2019 Jan 7;37(2):333-342. doi: 10.1016/j.vaccine.2018.08.043. Epub 2018 Dec 3.

PubMed ID: 30522906

Jahan ST, Sadat SMA, Yarahmadi M, Haddadi A. Potentiating Antigen Specific Immune Response by Targeted Delivery of the PLGA-Based Model Cancer Vaccine. Mol Pharm. 2019 Feb 4;16(2):498-509. doi: 10.1021/acs.molpharmaceut.8b00700. Epub 2019 Jan 23.

PubMed ID: 30477303

PubMed ID: 30571097

Lousada-Dietrich, S., Jogdand, P.S., Jepsen, S., Pinto, V.V., Ditlev, S.B., Christiansen, M., Larsen, S.O., Fox, C.B., Raman, V.S., Howard, R.F., Vedvick, T.S., Ireton, G., Carter, D., Reed, S.G., Theisen, M. (2011) A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine.

PubMed ID: 21349366

Coler, R.N., Bertholet, S., Moutaftsi, M., Guderian, J.A., Windish, H.P., Baldwin, S.L., Laughlin, E.M., Duthie, M.S., Fox, C.B., Carter, D., Friede, M., Vedvick, T.S., Reed, S.G. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 6:e16333.

PubMed ID: 21298114

Anderson, R.C., Fox, C.B., Dutill, T.S., Shaverdian, N., Evers, T.L., Poshusta, G.R., Chesko, J., Coler, R.N., Friede, M., Reed, S.G., Vedvick, T.S. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces. 75:123-32.

PubMed ID: 19748238

Coler, R.N., S.L. Baldwin, N. Shaverdian, S. Bertholet, S.J. Reed, V.S. Raman, X. Lu, J. DeVos, K. Hancock, J.M. Katz, T.S. Vedvick, M.S. Duthie, C.H. Clegg, N. Van Hoeven, and S.G. Reed. (2010). A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5:e13677.

PubMed ID: 21060869

Fox, C.B., Friede, M., Reed, S.G., Ireton, G.C. (2010) Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem. 53:303-21

PubMed ID: 20593273

Certificates of Analysis

Certificate of Analysis(Lot No. 699800P-1MG-A-029and 5086PGA029)
Certificate of Analysis(Lot No. 699800P-5MG-A-029and 5086PHA029)
Certificate of Analysis(Lot No. 699800P-5MG-B-029and 5086PHB029)
Certificate of Analysis(Lot No. 699800P-5MG-B-029and 5086PHB029)
Certificate of Analysis(Lot No. 699800P-25MG-A-029and 5086PJA029)
Certificate of Analysis(Lot No. 699800P-1MG-C-029and 5086PGC029)
Certificate of Analysis(Lot No. 699800P-5MG-C-029and 5086PHC029)
Certificate of Analysis(Lot No. 699800P-25MG-B-029and 5086PJB029)
Certificate of Analysis(Lot No. 699800P-25MG-C-029and 5086PJC029)
Certificate of Analysis(Lot No. 699800P-1MG-D-029and 5086PGD029)
Certificate of Analysis(Lot No. 699800P-5MG-D-029and 5086PHD029)
Certificate of Analysis(Lot No. 699800P-CONF-A-029and 5086PWA029)
Certificate of Analysis(Lot No. 699800P-CONF-B-029and 5086PWB029)
Certificate of Analysis(Lot No. 699800P-5MG-E-029and 5086PHE029)
Certificate of Analysis(Lot No. 699800P-1MG-E-029and 5086PGE029)
Certificate of Analysis(Lot No. 699800P-CONF-C-029and 5086PWC029)
Certificate of Analysis(Lot No. 699800P-1MG-B-029and 5086PGB029)
Certificate of Analysis(Lot No. 699800P-1MG-G-029and 5086PGG029)
Certificate of Analysis(Lot No. 699800P-1MG-F-029and 5086PGF029)
Certificate of Analysis(Lot No. 699800P-1MG-H-029and 5086PGH029)
Certificate of Analysis(Lot No. 699800P-5MG-G-029and 5086PHG029)
Certificate of Analysis(Lot No. 699800P-1MG-A-031and 5086PGA031)
Certificate of Analysis(Lot No. 699800P-5MG-A-033and 5086PHA033)
Certificate of Analysis(Lot No. 699800P-5MG-A-032and 5086PHA032)

Base Price:${originalprice|money}

Custom Packaging:(${concentration} @$4.00/ea. + $100)${custompackagingtotal|money}

Packaging:${concentration}

Item Total:${totalprice|money}

(Sales Tax may apply)

Please select an option above.

Selected Product${sku} - ${concentration}

品牌介绍

Avanti Polar Lipids 阿凡提极地脂质公司，有着50年的历史，创造了最高纯度的脂类产品。我们对高质量和独特的产品的热情只会被我们在市场上的良好声誉所超越。 Since its spartan beginnings in a 900 square foot rented laboratory space, Avanti has established a 25 acre manufacturing campus comprised of 11 buildings which house our manufacturing, formulation, analytical, and administrative units. Operations were moved to the current site in Alabaster, Alabama, in 1990, and we have continued to expand our capabilities and attract talented personnel to develop new and innovative products. With over 120 employees diligently working to provide high quality revolutionary lipid products, we have successfully grown our product offering to well over 2000 unique lipids, antibodies, and lipid research tools while maintaining the founding vision established by Dr. Shaw in 1967. Quite an accomplishment considering we started with a catalog containing only a handful of lipids isolated from plant and animal sources. 品牌货号名称规格 Avanti Polar Lipids 860853 16:0 Azido Coenzyme A 1mg Avanti Polar Lipids 900415 Oleic Acid (18-azido) 5mg 25mg Avanti Polar Lipids 900414 16:0(alkyne)-18:1 PE 1mg 5mg Avanti Polar Lipids 900413 16:0(alkyne)-18:1 PC 1mg 5mg Avanti Polar Lipids 860831 C6(6-azido) Ceramide 5mg Avanti Polar Lipids 860832 C6(6-azido) LacCer 5mg Avanti Polar Lipids 860833 C6(6-azido) GalCer 5mg Avanti Polar Lipids 860834 C6(6-azido) GluCer 5mg Avanti Polar Lipids 900600 PhotoClick Sphingosine 100ug 250ug Avanti Polar Lipids 810340 Click PI(4,5)P2-azido 100ug Avanti Polar Lipids 900400 Palmitic acid (15-yne) 1mg 5mg Avanti Polar Lipids 900404 pacFA Ceramide 1mg Avanti Polar Lipids 900405 pacFA GlcCer 1mg Avanti Polar Lipids 900406 pacFA GalCer 1mg Avanti Polar Lipids 900407 16:0-pacFA PC 1mg

公司介绍

品牌分类

Solvent Mixtures 阳离子脂质（转染） Isoprenoids 极光® 金探针 Bacterial Lipids Enantiomers of Natural Lipids Photoswitchable Lipids 新产品脂质试剂盒

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.avantilipids.com